Cromos Pharma Adds Israel to Its Geographic Coverage

BEIT-DAGAN, ISRAEL--Cromos Pharma, a premier regional contract research organization (CRO), announced today that it started clinical trial operations in the State of Israel.

"Israel is at the forefront of medical innovation," said Dr. Vlad Bogin, Cromos Pharma's CEO. "We are very excited to enter its market and view this as a major opportunity to expand our capabilities in running cutting-edge pharmaceutical and medical device trials."

"This expansion in geographic coverage possesses one important added advantage: about one quarter of Israel's population is Russian-speaking and is of a very similar sociocultural background as are our present-day patients, investigators and staff," concluded Dr. Andrey Tarakanov, Cromos Pharma's Managing Director.

About Cromos Pharma, LLC
Cromos Pharma, LLC is a premier contract research organization (CRO) with operations in Ukraine, Russia, Belarus, Georgia, the Baltic States and Eastern Europe and a business development office in the United States. The company provides a full spectrum of trial-related services, which include regulatory approvals, medical writing, feasibility assessments, monitoring, project management and warehousing. Cromos Pharma, LLC is a privately owned company.



Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.